ArticleCurrent protocols2025
Adaptable Immunofluorescence Protocol for Muscle Fiber Typing in FFPE Human and Mouse Skeletal Muscle and Intact Mouse Hindlimbs.
Article in Current protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Standardization of Immunohistochemistry Using an Anti-WASLB Antibody in the Skeletal Muscle of Teleost Fish.Current protocols · 2026Article
- Adaptable Immunofluorescence Protocol for Muscle Fiber Typing in FFPE Human and Mouse Skeletal Muscle and Intact Mouse Hindlimbs.Current protocols · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skeletal muscle fiber type composition affects muscle function, metabolism, and disease vulnerability. In addition, muscle fiber type analysis informs disease diagnosis and underlying pathophysiology. Multiple methodologies can be used to assess muscle fiber type; however, immunofluorescence (IF) for myosin heavy chain (MyHC) isoforms is the most widely used modern approach due to its relative ease, time-effectiveness, single-cell resolution, and capacity to preserve spatial positioning within the native tissue architecture. Here, we present a protocol for IF for MyHC labeling on formalin-fixed paraffin-embedded (FFPE) mouse and human muscle sections. We then describe a modified procedure for fiber type analysis of the intact mouse lower hindlimb, enabling high-throughput muscle composition and morphological analysis across distinct muscles on a single tissue section. Traditionally, IF labeling for MyHC isoforms required fresh tissue flash-frozen in liquid nitrogen-cooled isopentane, which, while effective, presents challenges for sample processing and preservation, long-term storage, transport, and biosafety. Comparatively, embedding tissue in paraffin after formalin fixation streamlines clinical workflows, preserves morphology, improves long-term sample stability, and simplifies sample storage and transport. Furthermore, FFPE effectively inactivates most infectious agents, which can be retained in frozen sections. Thus, FFPE samples are typically safe for standard laboratory handling and are not classified as biohazardous. This approach can be adapted for use with a range of downstream applications, including integration of fiber type analysis with emerging next-generation techniques that favor FFPE samples. In sum, this method offers a robust alternative to traditional fresh-frozen protocols and allows for simultaneous fiber type analysis across multiple muscle tissues. © 2025 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol: Multiplex Immunofluorescence for MyHC Labeling in FFPE Skeletal Muscle Tissues Alternate Protocol 1: Immunofluorescence for MyHC 2x Labeling in FFPE Skeletal Muscle Tissues Alternate Protocol 2: Multiplex Immunofluorescence for MyHC Labeling in FFPE Whole Hindlimb Sections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.